Worldwide Exocrine Pancreatic Insufficiency Industry to 2030 –

DUBLIN–()–The “Exocrine Pancreatic Insufficiency (EPI) -Market Insights, Epidemiology and Market Forecast- 2030” drug pipelines has been added to’s offering.

Exocrine Pancreatic Insufficiency (EPI) -Market Insights, Epidemiology and Market Forecast- 2030′ report delivers an in-depth understanding of the Exocrine Pancreatic Insufficiency (EPI), historical and forecasted epidemiology as well as the Exocrine Pancreatic Insufficiency (EPI) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Exocrine Pancreatic Insufficiency (EPI) market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM Exocrine Pancreatic Insufficiency (EPI) market size from 2017 to 2030. The report also covers current Exocrine Pancreatic Insufficiency (EPI) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Exocrine Pancreatic Insufficiency (EPI) Diagnosis

The diagnostic approach to EPI can be addressed to evaluate the maldigestion of nutrients or to quantify the exocrine pancreatic secretion specifically. Two categories of tests can be distinguished: direct and indirect. Indirect tests assess the consequence of exocrine insufficiency, evaluating quantitative changes of pancreatic secretion. Direct tests evaluate the secretive production directly, and, despite their good sensitivity, are invasive, time-consuming, expensive, and not useful in monitoring the response to pancreatic enzyme replacement therapy (PERT). Moreover, they are not standardized because of lack of consensus about protocol, and present extensive variation in results, and are not widely available. The indirect tests includes Stool tests Coefficient of fat absorption, Fecal elastase-1 (FE-1), Stool chymotrypsin, Blood test Serum immunoreactive trypsinogen (IRT), and others whereas the direct tests for EPI includes Endoscopic secretin or CCK based pancreatic stimulation test, and Secretin-enhanced magnetic resonance cholangiopancreatography (s-MRCP).

Exocrine Pancreatic Insufficiency (EPI) Treatment

Patients with EPI may be treated with Pancreatic enzyme replacement therapy (PERT) to aid in the digestion and absorption of fats; PERT is recommended for patients with EPI to address weight loss, malnutrition, and steatorrhea. Briefly, treatment is primarily based on oral PERT regimens to correct malnutrition and improve symptoms. The current drugs that fall under PERT includes Creon, Zenpep, Pancreaze, Viokase, and Pertzye respectively, Underlying diseases leading to EPI should be treated, and lifestyle modifications should also be undertaken, including alcohol abstinence (to reduce pain and increase gastric lipase secretion) and supplementation of fat-soluble vitamins as needed. Dietary fat restriction is not necessary, especially for patients on enzyme supplementation. Frequent, low-volume meals are recommended, and difficult-to-digest foods such as legumes should be avoided.

It covers the details of conventional and current medical therapies available in the Exocrine Pancreatic Insufficiency (EPI) market for the treatment of the various types of Exocrine Pancreatic Insufficiency (EPI). It also provides the treatment guidelines and algorithms of the United States and Europe. The Exocrine Pancreatic Insufficiency (EPI) market report gives a thorough understanding of Exocrine Pancreatic Insufficiency (EPI) by including details such as disease definition, causes, risk factors, pathogenesis, and diagnosis.

Exocrine Pancreatic Insufficiency (EPI) Epidemiology

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Prevalence of Causative Indications of EPI and Prevalence of Exocrine Pancreatic Insufficiency scenario of Exocrine Pancreatic Insufficiency (EPI) in the 7MM market covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan from 2017 to 2030.

Key Findings

This section provides glimpse of the Exocrine Pancreatic Insufficiency (EPI) epidemiology in the 7MM.

  • In the 7MM, the highest prevalence of Causative Indications of EPI was observed in Type 2 Diabetes Mellitus which was estimated to be 67,892,836 cases in 2017 during the forecast period (2020-2030).
  • As per the estimates in Japan, 61,961, 66,261, 11,721, 25,319 patients were affected by Acute Pancreatitis, Chronic Pancreatitis, Cystic Fibrosis and Unresectable Pancreatic Cancer in 2017, respectively, which are anticipated to increase in the forecast period.
  • Acute Pancreatitis, Chronic Pancreatitis, Cystic Fibrosis and Unresectable Pancreatic Cancer are assumed to play the foremost role in the development of EPI.

Scope of the Report

  • The report covers the descriptive overview of Exocrine Pancreatic Insufficiency (EPI), explaining its causes, signs and symptoms, pathogenesis and currently available therapies.
  • Comprehensive insight has been provided into the Exocrine Pancreatic Insufficiency (EPI) epidemiology and treatment.
  • Additionally, an all-inclusive account of both the current and emerging therapies for Exocrine Pancreatic Insufficiency (EPI) are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
  • A detailed review of Exocrine Pancreatic Insufficiency (EPI) market; historical and forecasted is included in the report, covering the 7MM drug outreach.
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM Exocrine Pancreatic Insufficiency (EPI) market.

Report Highlights

  • In the coming years, Exocrine Pancreatic Insufficiency (EPI) market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Exocrine Pancreatic Insufficiency (EPI) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Major players are involved in developing therapies for Exocrine Pancreatic Insufficiency (EPI). Launch of emerging therapies will significantly impact the Exocrine Pancreatic Insufficiency (EPI) market.
  • Our in-depth analysis of the pipeline assets across different stages of development (phase III and phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Companies Mentioned

  • Digestive Care
  • AbbVie
  • Nestle
  • Janssen Pharmaceuticals
  • Aptalis Pharma/Forest Laboratories
  • Alcresta Therapeutics
  • Aptalis Pharma/Forest Laboratories
  • Chiesi Farmaceutici
  • AzurRx BioPharma

For more information about this drug pipelines report visit


About the Author: Biotech Today

You might like